

Global Lung Cancer Therapeutic Market Research and Analysis, 2015-2021

<https://marketpublishers.com/r/G8B484394D7EN.html>

Date: February 2017

Pages: 0

Price: US\$ 3,495.00 (Single User License)

ID: G8B484394D7EN

Abstracts

The Global Lung Cancer Therapeutic Market is expected to grow at the CAGR of 13.2 % during 2016-2021. The Global Lung Cancer Therapeutic Market is growing at a modest rate due to rise in incidence prevalence rate of Lung cancer across the globe. The adoption of lung cancer drugs and innovative lung surgeries are expected to boost the global lung cancer market. Huge demand is created by rising diagnostic centers across the globe. Investment and grants from government and private players are driving the market. Successful clinical trials and FDA approval are the key factors creating huge scope in Global Lung Cancer Therapeutic Market. Adoption of Lung Cancer Therapeutic Market drugs such as Platinol, Taxol, Gemzar, Alimta, Iressa, Xalkori & Tarceva is increasing. Personalized medicines and drug discovery & development has significant contribution in the growth of Lung Cancer Therapeutic Market.

Geographical Insights

North America and Europe has a considerable contribution to the growth of Global Lung Cancer Therapeutic Market followed by APAC region. The key driving forces include rising incidence of lung cancer Diseases and adoption of lung cancer drugs and surgeries across the globe. Emerging economies such as China, India, Japan, and Korea have most lung cancer patients and with improved healthcare system and healthcare spending APAC region looks promising for Global Lung Cancer Therapeutic Market. Improved standard of living, infrastructural development and favorable government policies are some other factors that will boost the APAC market. The report includes detailed Market Overview, Market Determinants, Company Profiling, Sector Analysis, Market Segmentation, Geographical Analysis, Pipeline Analysis, Patent Analysis, Strategic Recommendations, Key Company Analysis, Key Findings, Analyst

Insights and predictive analysis of the market.

Competitive Insights

The Global Lung Cancer Therapeutic Market companies include Boehringer Ingelheim, Abbvie, Eli Lilly, F. Hoffmann-La Roche GlaxoSmithKline, Merck Serono and Novartis. Lung Cancer Therapeutic companies are constantly focusing on R&D, partnerships, M&A, innovation and technological advancement.

Market Segmentation

Global Lung Cancer Therapeutic Market Research And Analysis

Platinol

Taxol

Gemzar

Alimta

Iressa

Hycamtin

Gilotrif

Taxotere

Xalkori

Navelbine

Avastin

Tarceva

Others

OMR Report covers

Comprehensive research methodology of Global Lung Cancer Market.

This report also includes detailed and extensive market overview with historical analysis & key analysts insights.

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the Global Lung Cancer Market.

Insights about market determinants which are stimulating the Global Lung Cancer Market.

Detailed and extensive market segments with regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Contents

REPORT SUMMARY

- 1.1. RESEARCH METHODS AND TOOLS
- 1.2. MARKET BREAKDOWN
 - 1.2.1. BY SEGMENTS
 - 1.2.2. BY GEOGRAPHY
 - 1.2.3. BY STAKEHOLDERS
 - 1.2.4. EXCEPTIONS

MARKET OVERVIEW AND INSIGHTS

- 2.1. DEFINITION
- 2.2. PIPELINE ANALYSIS
- 2.3. ANALYST INSIGHT
 - 2.3.1. KEY FINDINGS & CURRENT MARKET TRENDS
 - 2.3.2. RECOMMENDATION
 - 2.3.3. CONCLUSION
- 2.4. REGULATION
 - 2.4.1. UNITED STATES
 - 2.4.2. EUROPEAN UNION
 - 2.4.3. CHINA
 - 2.4.4. INDIA
 - 2.4.5. REST OF THE WORLD
- 2.5. PIPELINE ANALYSIS
 - 2.5.1. KEYTRUDA MK-3475 NON-SMALL CELL LUNG CANCER DRUG
 - 2.5.2. ATEZOLIZUMAB (ANTI-PDL1, RG7446, MPDL3280A) ROCHE
 - 2.5.3. RG6016 (ROCHE)
 - 2.5.4. TRASTUZUMAB EMTANSINE (T-DM1)
 - 2.5.5. RG7604 PIK3CA
 - 2.5.6. ALECTINIB (RG7853)
 - 2.5.7. OTHERS
- 2.6. NEWLY APPROVED DRUGS
 - 2.6.1. ALECENSA (ALECTINIB), ROCHE
 - 2.6.2. KEYTRUDA (PEMBROLIZUMAB), MERCK
 - 2.6.3. OPDIVO (NIVOLUMAB), BRISTOL-MYERS SQUIBB
 - 2.6.4. PORTRAZZA (NECITUMUMAB), ELI LILLY
 - 2.6.5. TAGRISSO (OSIMERTINIB), ASTRAZENECA

- 2.6.6. ABITREXATE (METHOTREXATE)
- 2.6.7. AVASTIN (BEVACIZUMAB)
- 2.6.8. DOCETAXEL
- 2.6.9. FOLEX (METHOTREXATE)
- 2.6.10. OTHERS

MARKET DETERMINANT

3.1. MOTIVATORS

- 3.1.1. RISE IN INCIDENCE & PREVALENCE RATE OF CANCER DISEASES
- 3.1.2. RISE IN INVESTMENT AND GRANTS FROM GOVERNMENT AND PRIVATE PLAYERS
- 3.1.3. RISE IN DIAGNOSTIC CENTERS ACROSS THE GLOBE
- 3.1.4. GROWTH IN PHARMACEUTICAL MARKET OF LUNG CANCER
- 3.1.5. RESEARCH & DEVELOPMENT IN LUNG CANCER MARKET
- 3.1.6. ADOPTION OF INNOVATIVE LUNG SURGERY
- 3.1.7. FDA CLEARANCE TO LUNG CANCER DRUGS
- 3.1.8. RISE IN ADOPTION OF PERSONALIZED MEDICINES
- 3.1.9. RISING MORTALITY RATE DUE TO LUNG CANCER

3.2. RESTRAINT

- 3.2.1. HIGH COST OF GLOBAL LUNG CANCER DRUGS AND SURGERIES
- 3.2.2. REIMBURSEMENT POLICIES MAY AFFECT THE GROWTH OF THE MARKET

3.3. OPPORTUNITY

- 3.3.1. UNTAPPED APAC REGION HAVE HUGE OPPORTUNITY FOR GLOBAL LUNG CANCER MARKET
- 3.3.2. SUCCESSFUL CLINICAL TRIALS AND FDA APPROVALS

MARKET SEGMENTATION

4.1. LUNG CANCER DRUGS MARKET RESEARCH AND ANALYSIS, 2015-2021, (\$ MILLIONS)

- 4.1.1. PLATINOL
- 4.1.2. TAXOL
- 4.1.3. GEMZAR
- 4.1.4. ALIMTA
- 4.1.5. IRESSA
- 4.1.6. HYCAMTIN
- 4.1.7. GILOTRIF

- 4.1.8. TAXOTERE
- 4.1.9. XALKORI
- 4.1.10. NAVELBINE
- 4.1.11. AVASTIN
- 4.1.12. TARCEVA
- 4.1.13. OTHERS

COMPETITIVE LANDSCAPE

- 5.1. KEY STRATEGIES
- 5.2. KEY COMPANY ANALYSIS

REGIONAL ANALYSIS

- 6.1. NORTH AMERICA
 - 6.1.1. UNITED STATES
 - 6.1.2. CANADA
 - 6.1.3. REST OF NORTH AMERICA
- 6.2. EUROPE
 - 6.2.1. UK
 - 6.2.2. GERMANY
 - 6.2.3. SPAIN
 - 6.2.4. FRANCE
 - 6.2.5. ITALY
 - 6.2.6. REST OF EUROPE
- 6.3. ASIA PACIFIC
 - 6.3.1. INDIA
 - 6.3.2. CHINA
 - 6.3.3. JAPAN
 - 6.3.4. REST OF ASIA PACIFIC
- 6.4. REST OF THE WORLD

COMPANY PROFILES

- 7.1. ABBVIE
 - 7.1.1. INTRODUCTION
 - 7.1.2. ABBVIE PRODUCT PORTFOLIO
 - 7.1.3. ABBVIE RECENT ACTIVITIES
- 7.2. AGENNIX

- 7.2.1. INTRODUCTION
- 7.2.2. AGENNIX PRODUCT PORTFOLIO
- 7.2.3. AGENNIX RECENT ACTIVITIES
- 7.3. AMGEN
 - 7.3.1. INTRODUCTION
 - 7.3.2. AMGEN PRODUCT PORTFOLIO
 - 7.3.3. AMGEN RECENT ACTIVITIES
- 7.4. ASTRAZENECA
 - 7.4.1. INTRODUCTION
 - 7.4.2. ASTRAZENECA PRODUCT PORTFOLIO
 - 7.4.3. ASTRAZENECA RECENT ACTIVITIES
- 7.5. BOEHRINGER INGELHEIM
 - 7.5.1. INTRODUCTION
 - 7.5.2. BOEHRINGER INGELHEIM PRODUCT PORTFOLIO
 - 7.5.3. BOEHRINGER INGELHEIM RECENT ACTIVITIES
- 7.6. CELGENE
 - 7.6.1. INTRODUCTION
 - 7.6.2. CELGENE PRODUCT PORTFOLIO
 - 7.6.3. CELGENE RECENT ACTIVITIES
- 7.7. CELLDEX
 - 7.7.1. INTRODUCTION
 - 7.7.2. CELLDEX PRODUCT PORTFOLIO
 - 7.7.3. CELLDEX RECENT ACTIVITIES
- 7.8. EISAI
 - 7.8.1. INTRODUCTION
 - 7.8.2. EISAI PRODUCT PORTFOLIO
 - 7.8.3. EISAI RECENT ACTIVITIES
- 7.9. ELI LILLY
 - 7.9.1. INTRODUCTION
 - 7.9.2. ELI LILLY PRODUCT PORTFOLIO
 - 7.9.3. ELI LILLY RECENT ACTIVITIES
- 7.10. F. HOFFMANN-LA ROCHE
 - 7.10.1. INTRODUCTION
 - 7.10.2. F. HOFFMANN-LA ROCHE PRODUCT PORTFOLIO
 - 7.10.3. F. HOFFMANN-LA ROCHE RECENT ACTIVITIES
- 7.11. GLAXOSMITHKLINE
 - 7.11.1. INTRODUCTION
 - 7.11.2. GLAXOSMITHKLINE PRODUCT PORTFOLIO
 - 7.11.3. GLAXOSMITHKLINE RECENT ACTIVITIES

7.12. HELSINN

7.12.1. INTRODUCTION

7.12.2. HELSINN PRODUCT PORTFOLIO

7.12.3. HELSINN RECENT ACTIVITIES

7.13. IMCLONE

7.13.1. INTRODUCTION

7.13.2. IMCLONE PRODUCT PORTFOLIO

7.13.3. IMCLONE RECENT ACTIVITIES

7.14. MERCK SERONO

7.14.1. INTRODUCTION

7.14.2. MERCK SERONO PRODUCT PORTFOLIO

7.14.3. MERCK SERONO RECENT ACTIVITIES

7.15. NOVARTIS

7.15.1. INTRODUCTION

7.15.2. NOVARTIS PRODUCT PORTFOLIO

7.15.3. NOVARTIS RECENT ACTIVITIES

7.16. ONCOGENEX

7.16.1. INTRODUCTION

7.16.2. ONCOGENEX PRODUCT PORTFOLIO

7.16.3. ONCOGENEX RECENT ACTIVITIES

7.17. OSI PHARMACEUTICALS

7.17.1. INTRODUCTION

7.17.2. OSI PHARMACEUTICALS PRODUCT PORTFOLIO

7.17.3. OSI PHARMACEUTICALS RECENT ACTIVITIES

7.18. PEREGRINE

7.18.1. INTRODUCTION

7.18.2. PEREGRINE PRODUCT PORTFOLIO

7.18.3. PEREGRINE RECENT ACTIVITIES

7.19. PFIZER, INC.

7.19.1. INTRODUCTION

7.19.2. PFIZER, INC. PRODUCT PORTFOLIO

7.19.3. PFIZER, INC. RECENT ACTIVITIES

7.20. PIERRE FABRE

7.20.1. INTRODUCTION

7.20.2. PIERRE FABRE PRODUCT PORTFOLIO

7.20.3. PIERRE FABRE RECENT ACTIVITIES

7.21. QIAGEN

7.21.1. INTRODUCTION

7.21.2. QIAGEN PRODUCT PORTFOLIO

- 7.21.3. QIAGEN RECENT ACTIVITIES
- 7.22. ROCHE
 - 7.22.1. INTRODUCTION
 - 7.22.2. ROCHE PRODUCT PORTFOLIO
 - 7.22.3. ROCHE RECENT ACTIVITIES
- 7.23. SANOFI
 - 7.23.1. INTRODUCTION
 - 7.23.2. SANOFI PRODUCT PORTFOLIO
 - 7.23.3. SANOFI RECENT ACTIVITIES
- 7.24. SYNTA
 - 7.24.1. INTRODUCTION
 - 7.24.2. SYNTA PRODUCT PORTFOLIO
 - 7.24.3. SYNTA RECENT ACTIVITIES
- 7.25. TELIK
 - 7.25.1. INTRODUCTION
 - 7.25.2. TELIK PRODUCT PORTFOLIO
 - 7.25.3. TELIK RECENT ACTIVITIES
- 7.26. TEVA PHARMACEUTICAL
 - 7.26.1. INTRODUCTION
 - 7.26.2. TEVA PHARMACEUTICAL PRODUCT PORTFOLIO
 - 7.26.3. TEVA PHARMACEUTICAL RECENT ACTIVITIES

List Of Tables

LIST OF TABLES

Table # 1 GLOBAL LUNG CANCER DRUGS MARKET RESEARCH AND ANALYSIS, 2015-2021, (\$ MILLIONS)

Table # 2 GLOBAL PLATINOL MARKET RESEARCH AND ANALYSIS, 2015-2021, (\$ MILLIONS)

Table # 3 GLOBAL TAXOL MARKET RESEARCH AND ANALYSIS, 2015-2021, (\$ MILLIONS)

Table # 4 GLOBAL GEMZAR MARKET RESEARCH AND ANALYSIS, 2015-2021, (\$ MILLIONS)

Table # 5 GLOBAL ALIMTA MARKET RESEARCH AND ANALYSIS, 2015-2021, (\$ MILLIONS)

Table # 6 GLOBAL IRESSA MARKET RESEARCH AND ANALYSIS, 2015-2021, (\$ MILLIONS)

Table # 7 GLOBAL HYCAMTIN MARKET RESEARCH AND ANALYSIS, 2015-2021, (\$ MILLIONS)

Table # 8 GLOBAL GILOTRIF MARKET RESEARCH AND ANALYSIS, 2015-2021, (\$ MILLIONS)

Table # 9 GLOBAL TAXOTERE MARKET RESEARCH AND ANALYSIS, 2015-2021, (\$ MILLIONS)

Table # 10 GLOBAL XALKORI MARKET RESEARCH AND ANALYSIS, 2015-2021, (\$ MILLIONS)

Table # 11 GLOBAL NAVELBINE MARKET RESEARCH AND ANALYSIS, 2015-2021, (\$ MILLIONS)

Table # 12 GLOBAL AVASTIN MARKET RESEARCH AND ANALYSIS, 2015-2021, (\$ MILLIONS)

Table # 13 GLOBAL TARCEVA MARKET RESEARCH AND ANALYSIS, 2015-2021, (\$ MILLIONS)

Table # 14 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2015-2021, (\$ MILLIONS)

Table # 15 ABBVIE PRODUCT PORTFOLIO

Table # 16 ABBVIE RECENT ACTIVITIES

Table # 17 AGENNIX PRODUCT PORTFOLIO

Table # 18 AGENNIX RECENT ACTIVITIES

Table # 19 AMGEN PRODUCT PORTFOLIO

Table # 20 AMGEN RECENT ACTIVITIES

Table # 21 ASTRAZENECA PRODUCT PORTFOLIO

Table # 22 ASTRAZENECA RECENT ACTIVITIES

Table # 23 BOEHRINGER INGELHEIM PRODUCT PORTFOLIO

Table # 24 BOEHRINGER INGELHEIM RECENT ACTIVITIES

Table # 25 CELGENE PRODUCT PORTFOLIO

Table # 26 CELGENE RECENT ACTIVITIES

Table # 27 CELLDEX PRODUCT PORTFOLIO

Table # 28 CELLDEX RECENT ACTIVITIES

Table # 29 EISAI PRODUCT PORTFOLIO

Table # 30 EISAI RECENT ACTIVITIES

Table # 31 EISAI/ELI LILLY PRODUCT PORTFOLIO

Table # 32 EISAI/ELI LILLY RECENT ACTIVITIES

Table # 33 F. HOFFMANN-LA ROCHE PRODUCT PORTFOLIO

Table # 34 F. HOFFMANN-LA ROCHE RECENT ACTIVITIES

Table # 35 GLAXOSMITHKLINE PRODUCT PORTFOLIO

Table # 36 GLAXOSMITHKLINE RECENT ACTIVITIES

Table # 37 HELSINN PRODUCT PORTFOLIO

Table # 38 HELSINN RECENT ACTIVITIES

Table # 39 IMCLONE PRODUCT PORTFOLIO

Table # 40 IMCLONE RECENT ACTIVITIES

Table # 41 MERCK SERONO PRODUCT PORTFOLIO

Table # 42 MERCK SERONO RECENT ACTIVITIES

Table # 43 NOVARTIS PRODUCT PORTFOLIO

Table # 44 NOVARTIS RECENT ACTIVITIES

Table # 45 ONCOGENEX PRODUCT PORTFOLIO

Table # 46 ONCOGENEX RECENT ACTIVITIES

Table # 47 OSI PHARMACEUTICALS PRODUCT PORTFOLIO

Table # 48 OSI PHARMACEUTICALS RECENT ACTIVITIES

Table # 49 PEREGRINE PRODUCT PORTFOLIO

Table # 50 PEREGRINE RECENT ACTIVITIES

Table # 51 PFIZER, INC. PRODUCT PORTFOLIO

Table # 52 PFIZER, INC. RECENT ACTIVITIES

Table # 53 PIERRE FABRE PRODUCT PORTFOLIO

Table # 54 PIERRE FABRE RECENT ACTIVITIES

Table # 55 QIAGEN PRODUCT PORTFOLIO

Table # 56 QIAGEN RECENT ACTIVITIES

Table # 57 ROCHE PRODUCT PORTFOLIO

Table # 58 ROCHE RECENT ACTIVITIES

Table # 59 SANOFI PRODUCT PORTFOLIO

Table # 60 SANOFI RECENT ACTIVITIES

Table # 61 SYNTA PRODUCT PORTFOLIO

Table # 62 SYNTA RECENT ACTIVITIES

Table # 63 TELIK PRODUCT PORTFOLIO

Table # 64 TELIK RECENT ACTIVITIES

Table # 65 TEVA PHARMACEUTICAL PRODUCT PORTFOLIO

Table # 66 TEVA PHARMACEUTICAL RECENT ACTIVITIES

List Of Figures

LIST OF FIGURES

Figure # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2015-2021

Figure # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2015-2021

Figure # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2015-2021

Figure # 4 REST OF NORTH AMERICA MARKET RESEARCH AND ANALYSIS,
2015-2021

Figure # 5 EUROPE MARKET RESEARCH AND ANALYSIS, 2015-2021

Figure # 6 UK MARKET RESEARCH AND ANALYSIS, 2015-2021

Figure #7 GERMANY MARKET RESEARCH AND ANALYSIS, 2015-2021

Figure #8 SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2021

Figure # 9 FRANCE MARKET RESEARCH AND ANALYSIS, 2015-2021

Figure # 10 SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2021

Figure # 11 ITALY MARKET RESEARCH AND ANALYSIS, 2015-2021

Figure # 12 REST OF EUROPE MARKET RESEARCH AND ANALYSIS, 2015-2021

Figure # 13 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2015-2021

Figure # 14 INDIA MARKET RESEARCH AND ANALYSIS, 2015-2021

Figure # 15 CHINA MARKET RESEARCH AND ANALYSIS, 2015-2021

Figure # 16 JAPAN MARKET RESEARCH AND ANALYSIS, 2015-2021

Figure # 17 ROPAC MARKET RESEARCH AND ANALYSIS, 2015-2021

Figure # 18 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS,
2015-2021

I would like to order

Product name: Global Lung Cancer Therapeutic Market Research and Analysis, 2015-2021

Product link: <https://marketpublishers.com/r/G8B484394D7EN.html>

Price: US\$ 3,495.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8B484394D7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970